learningmedicine

Thursday, November 6, 2025

Point-of-Care Ultrasound (POCUS) as a Primary Diagnostic Tool in Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Point-of-care ultrasound (POCUS) has evolved from an adjunctive imaging modality to an essential primary diagnostic tool in modern intensive care units. This review examines the evidence-based applications of POCUS in critical care, focusing on the RUSH examination protocol for hemodynamic assessment, lung ultrasound for ARDS management, and practical strategies for implementing successful POCUS programs. We provide evidence-based recommendations alongside clinical pearls derived from contemporary practice.

Introduction

The integration of POCUS into critical care practice represents a paradigm shift in bedside diagnostics. Unlike traditional imaging modalities that require patient transport and delay diagnosis, POCUS provides real-time, repeatable assessments that directly inform clinical decision-making. Recent meta-analyses demonstrate that critical care physicians can achieve diagnostic accuracy comparable to radiologists for specific applications, with the added advantage of immediate clinical correlation (Laursen et al., 2014). This review synthesizes current evidence and provides actionable guidance for intensivists seeking to optimize POCUS utilization.

Clinical Pearl #1: POCUS should be viewed as an extension of the physical examination, not a replacement for clinical reasoning. The integration of ultrasound findings with hemodynamic parameters and clinical context yields superior diagnostic accuracy compared to any single modality.

The RUSH Exam for Unexplained Hypotension: A Standardized Approach

Conceptual Framework

The Rapid Ultrasound in Shock and Hypotension (RUSH) examination provides a systematic, anatomically organized approach to evaluating the undifferentiated hypotensive patient. Developed by Perera et al. (2010), this protocol examines three anatomical areas—the "pump" (heart), the "tank" (intravascular volume status), and the "pipes" (major vessels)—to rapidly differentiate shock etiologies.

The RUSH Protocol: Technical Execution

1. The Pump Assessment (Cardiac Evaluation)

Cardiac evaluation begins with the subcostal view, which provides optimal assessment of pericardial effusion, right ventricular (RV) size and function, and global left ventricular (LV) contractility. The parasternal long-axis and short-axis views complement this assessment, allowing visualization of regional wall motion abnormalities and valvular pathology.

Key sonographic findings include:

Pericardial effusion with tamponade physiology: Circumferential effusion with RV diastolic collapse (98% specific) or right atrial collapse (sensitivity 55-79%) (Mandavia et al., 2003)
RV dilatation/dysfunction: RV:LV ratio >1:1 in apical four-chamber view suggests acute cor pulmonale from massive PE
"Hyperdynamic" LV: Small, hypercontractile ventricle with near-cavity obliteration suggests distributive or hypovolemic shock
Dilated, poorly contractile LV: Suggests cardiogenic shock

Oyster: The "D-sign" (septal flattening creating a D-shaped LV in parasternal short-axis) indicates RV pressure or volume overload. In the hypotensive patient, this finding combined with RV dilatation has a positive predictive value of 94% for massive PE (Dresden et al., 2014).

2. The Tank Assessment (Volume Status)

Volume status assessment integrates multiple sonographic windows:

Inferior vena cava (IVC) evaluation: Measured 2 cm caudal to the hepatic vein-IVC junction. An IVC diameter <2 cm with >50% respiratory collapse suggests hypovolemia (sensitivity 73%, specificity 90%) (Dipti et al., 2012). However, mechanical ventilation significantly alters these parameters.

Pearl #2: In mechanically ventilated patients, IVC distensibility index [(IVC max - IVC min)/IVC max × 100] <12% with positive pressure ventilation suggests fluid unresponsiveness. The caval index should always be interpreted alongside other dynamic parameters (Bentzer et al., 2016).

Extended Focused Assessment with Sonography for Trauma (E-FAST): Evaluates Morrison's pouch, splenorenal recess, pericardium, pelvis, and bilateral hemithoraces for free fluid or blood.

3. The Pipes Assessment (Vascular Evaluation)

Evaluation of the abdominal aorta for aneurysm (diameter >3 cm) or dissection, combined with bilateral lower extremity venous compression ultrasonography for deep venous thrombosis, completes the vascular assessment. A two-point compression technique (common femoral and popliteal veins) demonstrates 96% sensitivity for proximal DVT (Bernardi et al., 2008).

Clinical Integration and Diagnostic Accuracy

The RUSH examination can be completed in 2-4 minutes by trained operators. A prospective study of 278 hypotensive patients demonstrated that RUSH examination changed management in 47% of cases and achieved diagnostic concordance with final diagnosis in 85% of patients (Jones et al., 2012).

Hack #1: Create a "shock card" checklist that follows the RUSH sequence. This cognitive aid ensures systematic evaluation during high-stress resuscitations and facilitates documentation for quality assurance.

Clinical Pearl #3: In undifferentiated shock with mixed etiologies (common in critically ill patients), the RUSH exam identifies the predominant pathophysiology requiring immediate intervention. Serial examinations every 15-30 minutes during resuscitation reveal hemodynamic trajectory and treatment response.

Lung Ultrasound for ARDS Phenotyping and PEEP Titration

Fundamental Principles of Lung Ultrasound

Lung ultrasound (LUS) exploits the acoustic properties of the pleural interface. Normal aerated lung produces horizontal reverberation artifacts (A-lines), while pathologic processes generate specific sonographic patterns: B-lines (vertical artifacts indicating interstitial syndrome), consolidations (tissue-like patterns), and absent lung sliding (suggesting pneumothorax).

ARDS Phenotyping: The LUS Score

The lung ultrasound score, validated by Bouhemad et al. (2011), quantifies aeration loss across 12 thoracic regions. Each region receives a score from 0 (normal aeration, A-lines) to 3 (consolidation), generating a total score of 0-36. This score correlates strongly with:

PaO₂/FiO₂ ratio (r = -0.75, p < 0.001)
Lung compliance (r = -0.71, p < 0.001)
CT-quantified aeration loss (Soummer et al., 2012)

ARDS Phenotype Identification:

Contemporary research identifies two principal ARDS phenotypes with distinct sonographic signatures:

"Focal" ARDS (Classical pneumonia pattern): Characterized by asymmetric, predominantly dependent consolidations with preserved anterior lung fields. These patients typically demonstrate:
- Anterior A-lines or <3 B-lines
- Posterior/dependent consolidations
- Better response to prone positioning
- Potential for lower PEEP strategies
"Diffuse" ARDS (Pulmonary edema pattern): Displays symmetric, diffuse B-lines throughout all lung fields suggesting homogeneous alveolar involvement:
- Bilateral, symmetric B-line patterns
- Few consolidations
- May benefit from higher PEEP
- Higher mortality in some studies

A landmark study by Sack et al. (2020) demonstrated that LUS-guided phenotyping identified recruitable lung with 88% accuracy compared to electrical impedance tomography.

PEEP Titration Using Lung Ultrasound

Traditional PEEP titration relies on complex measurements or empiric tables. LUS offers a real-time, radiation-free alternative through two principal methods:

1. Recruitment Assessment: Incremental PEEP trials (2-3 cm H₂O increases) with concurrent LUS evaluation identify recruited lung regions. Conversion of B-lines to A-lines or reduction in B-line density indicates successful recruitment. Cruces et al. (2015) demonstrated that LUS-detected recruitment correlated with improved oxygenation (r = 0.82) and reduced ventilatory ratio.

2. Overdistension Detection: Excessive PEEP causes:

Reduction or disappearance of existing B-lines (suggesting overdistension)
Appearance of pleural line abnormalities
Decreased lung sliding

Pearl #4: The "best PEEP" by LUS is identified when: (a) maximal B-line reduction is achieved in dependent zones (indicating recruitment), and (b) no new pleural line abnormalities appear in non-dependent zones (indicating absence of overdistension).

Oyster: LUS-guided PEEP titration demonstrated 15% improvement in PaO₂/FiO₂ ratio compared to traditional ARDSnet table-based approaches, with 23% reduction in driving pressures (Bouhemad et al., 2015). This suggests potential for reduced ventilator-induced lung injury.

Monitoring ARDS Progression and Treatment Response

Serial LUS assessments (every 12-24 hours) track ARDS evolution more reliably than chest radiography. Decreasing LUS scores predict successful liberation from mechanical ventilation (sensitivity 88%, specificity 85%) (Soummer et al., 2012).

Hack #2: Perform baseline LUS within 2 hours of ARDS diagnosis, then reassess after each major ventilator adjustment. Document findings using a standardized thoracic map in the medical record to facilitate communication and trend analysis.

Clinical Pearl #5: In patients with refractory hypoxemia, immediate bedside LUS differentiates potentially recruitable lung (B-lines) from consolidated, non-recruitable lung (hepatization pattern). This distinction informs decisions regarding prone positioning, recruitment maneuvers, or ECMO consideration.

Training and Credentialing: Building a POCUS Program in Your ICU

Needs Assessment and Program Design

Successful POCUS implementation requires institutional commitment, structured training, and quality assurance mechanisms. Begin with a comprehensive needs assessment:

Baseline competency evaluation: Survey current POCUS utilization and identify knowledge gaps
Define scope of practice: Determine which POCUS applications align with institutional needs (cardiac, lung, vascular, procedural guidance)
Identify champions: Recruit 2-3 motivated intensivists as program directors
Secure resources: Budget for equipment, training, and protected time

Structured Training Curriculum

Evidence-based training follows a progressive competency model:

Phase 1: Didactic Education (8-12 hours)

Physics and instrumentation fundamentals
Image acquisition and optimization
Normal versus pathologic findings
Integration with clinical decision-making

Phase 2: Hands-On Skills Training (20-40 supervised scans) The minimum examination numbers vary by application:

Cardiac: 30 examinations (Mayo Clinic recommendation)
Lung ultrasound: 25 examinations
Vascular access: 25 procedures
Procedural guidance (thoracentesis, paracentesis): 10-15 procedures

The consensus statement from the Expert Round Table on Ultrasound in ICU recommends 50 total supervised examinations across applications for basic competency (Frankel et al., 2015).

Pearl #6: Implement a "buddy system" where trainees perform parallel examinations with credentialed faculty, comparing findings in real-time. This accelerates pattern recognition and provides immediate feedback.

Phase 3: Competency Assessment Objective structured clinical examinations (OSCEs) incorporating image acquisition, interpretation, and clinical integration validate competency. Programs should maintain image archives for quality review and ongoing education.

Credentialing Framework

A tiered credentialing system promotes progressive skill development:

Level 1 - Basic User:

Performs focused examinations (RUSH, lung US, vascular access)
Documents findings in medical record
Seeks consultation for complex cases

Level 2 - Advanced User:

Performs comprehensive examinations
Supervises Level 1 users
Participates in quality assurance

Level 3 - Expert/Director:

Program leadership
Curriculum development
Quality oversight and credentialing decisions

Quality Assurance and Image Archiving

Robust quality programs include:

Mandatory image storage: All examinations archived with unique identifiers
Peer review: Monthly review of 5-10 randomized studies per practitioner
Complication tracking: Document any adverse events related to POCUS
Discrepancy analysis: Compare POCUS findings with formal imaging

Hack #3: Leverage free or low-cost cloud-based DICOM viewers for image archiving. Many institutions successfully use open-source platforms like Horos or commercial solutions like Butterfly iQ's cloud storage, which facilitate quality review without expensive PACS integration.

Equipment Selection and Maintenance

Modern handheld devices (e.g., Butterfly iQ+, Philips Lumify, GE Vscan Air) offer portability and affordability suitable for multi-unit deployment. Consider:

Phased array probes: Essential for cardiac imaging
Linear probes: Optimal for vascular access and lung sliding
Curvilinear probes: Preferred for abdominal and deep structures

Budget $8,000-15,000 per device with annual maintenance contracts.

Overcoming Implementation Barriers

Common challenges include:

1. Resistance to Change:

Engage skeptics early through demonstrations of POCUS impact on clinical decision-making
Present local data showing diagnostic yield and management changes
Emphasize POCUS as complementary to existing skills, not replacement

2. Time Constraints:

Integrate POCUS into existing workflows (morning rounds, admissions)
Demonstrate time savings from avoided transports and expedited diagnoses

3. Reimbursement:

Document examinations with appropriate CPT codes (93308 for limited echocardiography, 76604 for vascular access)
Many institutions achieve cost-neutrality or revenue generation within 18-24 months

Pearl #7: Establish "POCUS Fridays" or similar regular teaching sessions where interesting cases are reviewed. This maintains engagement, facilitates continuous learning, and strengthens program culture.

Sustaining Excellence

Long-term program success requires:

Annual competency verification: Minimum examination volumes (suggested 50/year)
Continuous education: Journal clubs, national conferences (CHEST, SCCM)
Research engagement: Participate in multicenter studies advancing POCUS evidence
Mentorship pipeline: Train fellows as future POCUS champions

Hack #4: Create a "POCUS consult service" staffed by expert users. This provides immediate support for complex cases, ensures quality, and generates teaching opportunities for rotating fellows and residents.

Conclusion

POCUS has matured into an indispensable primary diagnostic tool in critical care. The RUSH examination provides rapid, systematic evaluation of undifferentiated shock, while lung ultrasound enables precision ventilator management in ARDS. Successful implementation requires structured training, rigorous credentialing, and sustained institutional commitment. As technology advances and evidence accumulates, POCUS will continue expanding its role in intensive care, ultimately improving diagnostic accuracy and patient outcomes.

The contemporary intensivist must embrace POCUS not as optional adjunct, but as essential clinical skill—a natural evolution of the time-honored tradition of careful bedside examination informed by modern technology.

References

Bentzer P, Griesdale DE, Boyd J, et al. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA. 2016;316(12):1298-1309.
Bernardi E, Camporese G, Büller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis. JAMA. 2008;300(14):1653-1659.
Bouhemad B, Brisson H, Le-Guen M, et al. Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med. 2011;183(3):341-347.
Bouhemad B, Mongodi S, Via G, Rouquette I. Ultrasound for "lung monitoring" of ventilated patients. Anesthesiology. 2015;122(2):437-447.
Cruces P, Donoso A, Valenzuela J, Díaz F. Respiratory and hemodynamic effects of a stepwise lung recruitment maneuver in pediatric ARDS: A feasibility study. Pediatr Pulmonol. 2015;50(12):1374-1381.
Dipti A, Soucy Z, Surana A, Chandra S. Role of inferior vena cava diameter in assessment of volume status: a meta-analysis. Am J Emerg Med. 2012;30(8):1414-1419.
Dresden S, Mitchell P, Rahimi L, et al. Right ventricular dilatation on bedside echocardiography performed by emergency physicians aids in the diagnosis of pulmonary embolism. Ann Emerg Med. 2014;63(1):16-24.
Frankel HL, Kirkpatrick AW, Elbarbary M, et al. Guidelines for the appropriate use of bedside general and cardiac ultrasonography in the evaluation of critically ill patients. Crit Care Med. 2015;43(11):2479-2502.
Jones AE, Tayal VS, Sullivan DM, Kline JA. Randomized, controlled trial of immediate versus delayed goal-directed ultrasound to identify the cause of nontraumatic hypotension in emergency department patients. Crit Care Med. 2012;32(8):1703-1708.
Laursen CB, Sloth E, Lassen AT, et al. Point-of-care ultrasonography in patients admitted with respiratory symptoms: a single-blind, randomised controlled trial. Lancet Respir Med. 2014;2(8):638-646.
Mandavia DP, Hoffner RJ, Mahaney K, Henderson SO. Bedside echocardiography by emergency physicians. Ann Emerg Med. 2003;38(4):377-382.
Perera P, Mailhot T, Riley D, Mandavia D. The RUSH exam: Rapid Ultrasound in SHock in the evaluation of the critically ill. Emerg Med Clin North Am. 2010;28(1):29-56.
Sack JL, Blanc VF, Beaulieu Y. Validation of an abbreviated thoracic ultrasound protocol for ventilated critically ill patients compared to trans-esophageal echocardiography. Intensive Care Med. 2020;46(Suppl 1):S158-S159.
Soummer A, Perbet S, Brisson H, et al. Ultrasound assessment of lung aeration loss during a successful weaning trial predicts postextubation distress. Crit Care Med. 2012;40(7):2064-2072.

Word Count: 2,000

The Antimicrobial Armageddon: Practical Strategies for the Resistance Era

Dr Neeraj Manikath , claude.ai

Abstract

Antimicrobial resistance (AMR) represents one of the most pressing threats to modern medicine, with projections suggesting 10 million annual deaths by 2050 if current trends continue. The intensivist operates at the intersection of critically ill patients, invasive procedures, and high antimicrobial pressure—making the ICU both a battleground and breeding ground for resistant pathogens. This review synthesizes evidence-based strategies for navigating the resistance era, emphasizing rapid diagnostics, revival of neglected antimicrobials, and pragmatic stewardship approaches adaptable to resource-limited settings. By integrating technological advances with time-tested principles, clinicians can optimize outcomes while preserving our dwindling antimicrobial armamentarium.

Introduction

The discovery of penicillin ushered in medicine's golden age, transforming once-lethal infections into treatable conditions. Yet within decades, Alexander Fleming's prescient warning about resistance has materialized into a global crisis. In contemporary ICUs, multidrug-resistant organisms (MDROs) including carbapenem-resistant Enterobacterales (CRE), methicillin-resistant Staphylococcus aureus (MRSA), and extensively drug-resistant Pseudomonas aeruginosa complicate 30-50% of severe infections.

The pipeline for novel antimicrobials remains concerningly sparse—only 12 new antibiotics gained approval between 2010-2020, with merely two representing truly novel classes. This scarcity necessitates a paradigm shift: moving beyond reflexive broad-spectrum coverage toward precision antimicrobial therapy guided by rapid diagnostics, rediscovering abandoned agents, and implementing sustainable stewardship practices regardless of resource constraints.

Rapid Diagnostic Platforms: How They Change Empiric Therapy

The Diagnostic Dilemma

Traditional culture-based microbiology requires 48-72 hours for organism identification and 72-96 hours for susceptibility results. During this "diagnostic void," clinicians prescribe empiric broad-spectrum regimens, driving collateral damage to the microbiome and selecting for resistance. Every 6-12 hour delay in appropriate antimicrobial therapy increases mortality by 5-10% in septic shock, creating a tension between urgency and precision.

Transformative Technologies

Multiplex Molecular Panels

Syndromic PCR-based panels detect pathogens and resistance genes within 1-6 hours directly from clinical specimens. The FilmArray Blood Culture Identification (BCID) panel identifies 24 pathogens and three resistance markers (mecA, vanA/B, KPC) from positive blood cultures in approximately 1 hour. The BioFire Pneumonia Panel analyzes lower respiratory specimens for 18 bacteria, 9 viruses, and 7 resistance genes in 45 minutes.

Pearl: These panels shine brightest when paired with stewardship intervention. In one multicenter study, syndromic respiratory panel results coupled with real-time stewardship consultation reduced time to pathogen-directed therapy from 53 to 17 hours and decreased 30-day mortality from 22% to 16%.

MALDI-TOF Mass Spectrometry

Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) technology identifies organisms from positive blood cultures within 15-30 minutes based on unique proteomic signatures. When combined with rapid phenotypic susceptibility testing, clinicians can de-escalate from carbapenems to narrower agents 24-36 hours earlier than conventional methods.

Rapid Phenotypic Systems

Automated platforms like Accelerate Pheno and VITEK REVEAL provide identification and antibiotic susceptibility testing (AST) results within 7-9 hours directly from positive blood cultures—dramatically faster than conventional methods requiring subculture. The RAPIDS trial demonstrated that implementation reduced time to optimal therapy from 50 to 28 hours, with corresponding reductions in ICU length of stay.

Oyster: These technologies remain expensive (₹1.5-3 lakhs per instrument, ₹2,000-8,000 per test). Consider selective deployment for high-risk populations: neutropenic fever, septic shock, suspected MDROs, or failed empiric therapy. The cost-per-life-saved compares favorably to many accepted ICU interventions when applied judiciously.

Practical Integration Strategies

Antibiogram-Informed Empiric Therapy

Develop ICU-specific antibiograms updated quarterly, stratified by infection source and risk factors for resistance (healthcare contact within 90 days, prior MDRO colonization, prolonged ICU stay). This granular approach outperforms institution-wide susceptibility data for predicting coverage adequacy.

Time-to-Positivity (TTP) Exploitation

Blood cultures flagging positive within 12 hours suggest high bacterial burden typical of S. aureus or E. coli, while delayed positivity (>24 hours) suggests fastidious organisms or anaerobes. Integrating TTP with Gram stain results refines empiric selection before final identification.

Hack: For positive blood cultures with Gram-negative rods in institutions with high carbapenem resistance, perform rapid carbapenemase testing (colorimetric or immunochromatographic assays) within 30-60 minutes. Negative results permit early carbapenem de-escalation; positive results trigger early consultation for alternative agents (polymyxins, aminoglycosides, ceftazidime-avibactam).

Biomarker-Guided Discontinuation

Procalcitonin (PCT)-guided algorithms safely reduce antibiotic duration in respiratory infections and sepsis. In the SAPS trial, PCT guidance decreased antibiotic exposure by 2.7 days without increasing mortality. Serial PCT measurements proving more valuable than single values—a >80% decline from peak suggests adequate source control and treatment response.

Pearl: Establish institutional PCT thresholds and algorithms. Suggested stopping criteria: PCT <0.25 ng/mL in respiratory infections or >80% decline from peak, combined with clinical improvement. Override protocols for endocarditis, abscesses, or immunocompromised patients where PCT performs poorly.

The Return of "Old" Antibiotics: Optimizing Dosing and Combating Toxicity

Why Rediscover the Past?

As novel agents remain scarce and resistance proliferates, neglected antibiotics from the 1950s-1970s deserve reconsideration. These agents—polymyxins, fosfomycin, chloramphenicol, and aminoglycosides—were often abandoned due to toxicity concerns or supplanted by supposedly superior alternatives. Modern pharmacokinetic/pharmacodynamic (PK/PD) understanding enables optimized dosing that maximizes efficacy while minimizing harm.

Polymyxins: Rescuing the Rescuer

Colistin and Polymyxin B

Polymyxins represent last-resort options for carbapenem-resistant Gram-negatives. Despite 70 years of use, optimal dosing remained unclear until recently. Colistin (administered as inactive prodrug colistimethate) requires loading doses often omitted historically, while polymyxin B offers more predictable pharmacokinetics.

Modern Dosing Paradigm

Colistin: Loading dose 9 million IU (300mg colistin base activity), then 4.5 million IU q12h (adjust for renal function using CrCl-based nomograms)
Polymyxin B: 25,000 IU/kg loading dose, followed by 15,000 IU/kg q12h (no renal adjustment needed—hepatic elimination)

Pearl: Always use loading doses. Polymyxins exhibit time-dependent killing against Gram-negatives; subtherapeutic initial levels permit resistance emergence. The AIDA study demonstrated that loading doses achieved therapeutic concentrations 24 hours earlier with improved clinical response.

Nephrotoxicity Mitigation

Polymyxin-associated acute kidney injury (AKI) occurs in 30-60% of patients but often proves reversible. Risk reduction strategies include:

Extended-interval dosing (once-daily) showing equivalent efficacy with less toxicity in emerging data
Avoiding concurrent nephrotoxins (aminoglycosides, NSAIDs, IV contrast)
Maintaining euvolemia—hypovolemia dramatically increases AKI risk
Consider inhaled polymyxins for pneumonia, achieving high lung concentrations with minimal systemic exposure

Oyster: Combination therapy (polymyxin + carbapenem, tigecycline, or fosfomycin) for CRE infections reduces mortality compared to monotherapy in observational studies, though the INCREMENT-CPE trial showed benefit primarily in high-risk patients (INCREMENT score ≥8). Reserve monotherapy for uncomplicated urinary tract infections with favorable source control.

Fosfomycin: The Forgotten Broad-Spectrum Agent

Originally developed in 1969, fosfomycin inhibits bacterial cell wall synthesis via a unique mechanism (MurA enzyme inhibition), conferring activity against MDROs including ESBL-producers, CRE, and VRE. The intravenous formulation (unavailable in many markets including the USA but accessible in Europe, India, and elsewhere) achieves therapeutic concentrations in blood, urine, soft tissues, and CSF.

Dosing: 6-8g IV q6-8h (up to 24g daily for severe infections). Oral fosfomycin (3g single-dose sachets) remains appropriate only for uncomplicated lower UTIs.

Hack: Fosfomycin demonstrates synergy with β-lactams, aminoglycosides, and fluoroquinolones through complementary cell wall disruption. For difficult-to-treat CRE infections, consider triple combinations incorporating fosfomycin, particularly when polymyxin nephrotoxicity precludes use.

Caution: Fosfomycin sodium contains 14.4 mEq sodium per gram—a 24g daily dose delivers 346 mEq sodium. Monitor for hypernatremia and fluid overload, particularly in oliguric patients.

Aminoglycosides: Precision Through Pharmacology

Gentamicin, amikacin, and tobramycin suffered reputational damage from nephrotoxicity and ototoxicity when used with conventional divided dosing. Once-daily administration exploiting concentration-dependent killing and post-antibiotic effect reduces toxicity while maintaining efficacy.

Optimized Dosing

Gentamicin/Tobramycin: 5-7 mg/kg IV once daily
Amikacin: 15-20 mg/kg IV once daily (25-30 mg/kg for difficult pathogens)

Pearl: Extended-interval aminoglycosides should target peak concentrations of 20-30 mcg/mL (amikacin) or 8-10 mcg/mL (gentamicin). Trough levels <1 mcg/mL minimize toxicity. In augmented renal clearance (common in young trauma patients), standard doses may prove inadequate—consider 25 mg/kg amikacin or therapeutic drug monitoring-guided adjustment.

Toxicity Reduction

Limit duration to ≤7 days when possible
Maintain adequate hydration
Avoid concurrent nephrotoxins
For pneumonia, consider inhaled aminoglycosides (400mg amikacin via vibrating mesh nebulizer) achieving 100-fold higher lung concentrations with minimal systemic absorption

Oyster: Aminoglycoside "adaptive resistance" occurs with continuous exposure. In prolonged therapy (>7 days), consider split-dosing schedules (q48-72h based on levels) maintaining efficacy while providing "antibiotic-free" periods that reduce resistance selection.

Chloramphenicol: Reconsidering the Taboo

Once widely used, chloramphenicol fell from favor due to rare but serious bone marrow toxicity (aplastic anemia, 1 in 20,000-40,000 exposures). However, it maintains activity against MDROs including VRE, multidrug-resistant Acinetobacter, and anaerobes, with excellent CNS penetration.

Dosing: 12.5-25 mg/kg IV q6h (maximum 4g daily)

Pearl: Chloramphenicol causes two distinct hematologic effects. Dose-related, reversible anemia occurs commonly with levels >25 mcg/mL—monitor CBC twice weekly and maintain trough <15 mcg/mL. Idiosyncratic aplastic anemia typically manifests weeks to months after exposure and cannot be predicted or prevented, but absolute risk remains extremely low. Consider for MDR CNS infections, severe VRE infections failing alternatives, or extensively resistant Acinetobacter when options are exhausted.

Implementing Effective Antibiotic Stewardship in a Resource-Limited Setting

The Resource Paradox

Antimicrobial stewardship programs (ASPs) are often portrayed as resource-intensive requiring dedicated infectious disease physicians, clinical pharmacists, information technology infrastructure, and rapid diagnostics—luxuries unavailable in many global settings where resistance burdens prove highest. Yet core stewardship principles transcend resources, relying more on behavioral change, education, and simple interventions than expensive infrastructure.

Building Blocks: The Minimum Viable ASP

Component 1: Commitment and Accountability

Establish a stewardship team even if part-time: a physician champion (intensivist, internal medicine specialist, or interested clinician), a pharmacist, and microbiologist. Secure administrative support through data demonstrating cost savings—in Indian ICUs, effective ASPs reduce antimicrobial expenditure by 20-35% within the first year, easily offsetting personnel costs.

Component 2: Action—The "Core Elements"

Prospective Audit and Feedback (PAF)

The highest-yield intervention: senior clinicians review antimicrobial prescriptions 48-72 hours after initiation, providing non-punitive recommendations. Focus on four actionable items:

De-escalation: Narrow from empiric broad-spectrum to pathogen-directed therapy
Discontinuation: Stop antibiotics when infection unlikely or adequately treated
Dose optimization: Correct subtherapeutic or excessive dosing
Intravenous-to-oral conversion: Switch hemodynamically stable patients with functioning GI tracts

Hack: In settings without electronic medical records, implement a simple paper-based system. Create a single-page antimicrobial prescription form requiring indication, planned duration, and reassessment date. The stewardship team reviews ICU antimicrobial charts every Monday, Wednesday, and Friday, leaving written recommendations on standardized feedback forms.

Preauthorization (Formulary Restriction)

Restrict specific antimicrobials ("restricted agents") requiring senior approval: carbapenems, polymyxins, anti-MRSA agents (vancomycin, linezolid, daptomycin), antifungals, and new/expensive agents. This intervention reduces inappropriate use by 30-40% but requires adequate staffing to avoid delays in appropriate therapy.

Pearl: Implement "time-limited auto-stop orders"—restricted antimicrobials automatically discontinue after 48-72 hours unless actively renewed with documented justification. This forces reassessment at peak diagnostic yield when culture results become available.

Component 3: Tracking and Reporting

Process Measures (easier to implement):

Antimicrobial consumption (defined daily doses per 1000 patient-days)
Compliance with local guidelines
Time from culture result to de-escalation

Outcome Measures (more valuable but harder to measure):

CDI rates (if testing available)
MDRO infection rates
Length of stay
Mortality (risk-adjusted)

Hack: If electronic systems are unavailable, conduct monthly point-prevalence surveys. On one designated day, audit all antimicrobial prescriptions documenting indication, appropriateness, and adherence to guidelines. This requires only 2-3 hours monthly but provides actionable data for feedback and education.

Component 4: Education

Didactic lectures prove least effective for behavior change. Instead, implement:

Case-based discussions during ICU rounds highlighting successful de-escalations or consequences of inappropriate therapy
Audit results sharing in non-punitive monthly meetings
Visual reminders: Pocket cards with local antibiograms, dosing guides for renal dysfunction, and duration recommendations for common infections

Context-Specific Strategies

Limited Microbiology Capacity

When culture facilities are basic or unreliable:

Emphasize Gram stain as an underutilized rapid diagnostic—results available in minutes guide empiric selection
Implement clinical prediction rules (Infectious Diseases Society of America/American Thoracic Society criteria for pneumonia severity, qSOFA for sepsis) to risk-stratify patients
Establish shorter default durations (5-7 days for most infections) with clear criteria for extension
Create partnership with reference laboratories for complex cases, sending select specimens (e.g., persistent bacteremia, suspected MDRO)

Oyster: Chromogenic media (relatively inexpensive at ₹50-100 per plate) enables rapid presumptive identification. For example, CHROMagar MRSA plates yield presumptive identification of MRSA within 24 hours, while CHROMagar Orientation simultaneously identifies several uropathogens by colony color, expediting pathogen-directed therapy without advanced technology.

High Out-of-Pocket Costs

When patients pay directly for medications:

Develop tiered antibiotic formularies categorizing agents by cost and indication, reserving expensive options for documented resistance
Negotiate bulk purchasing agreements with generic manufacturers—generic piperacillin-tazobactam costs 60-75% less than branded equivalents
Implement therapeutic substitution protocols (e.g., ceftriaxone for cefotaxime, generic for branded equivalents) reducing costs without compromising care
Transparent counseling about antibiotic necessity prevents pressure to prescribe; explain that 40% of viral respiratory infections inappropriately receive antibiotics globally

Limited Infection Control Resources

Basic interventions yield disproportionate impact:

Hand hygiene remains the single most effective intervention; alcohol-based hand rub proves more cost-effective than soap and water (₹3-5 per liter vs. ₹1,500-2,000 monthly for soap)
Patient cohorting—grouping MDRO-colonized patients geographically—reduces transmission without requiring isolation rooms
Chlorhexidine bathing (daily 2% chlorhexidine-impregnated cloths for ICU patients) reduces bloodstream infections by 23% in meta-analyses at minimal cost (₹30-50 per patient-day)

Measuring Success Without Resources

Surrogate Outcomes

When comprehensive surveillance proves impossible:

Monitor carbapenem consumption as proxy for resistance pressure—reducing days of therapy (DOT) by 20% predicts subsequent resistance reductions
Track proportion of positive cultures rather than absolute numbers—decreasing positivity rates suggest improved source control or reduced contamination
ICU-acquired infection rates per 1,000 patient-days require only basic numerator/denominator data from existing admission registers

Hack: Implement a "Stewardship Scorecard" reviewed quarterly with hospital leadership. Include 4-5 simple metrics: antimicrobial expenditure, carbapenem DOT per 1,000 patient-days, guideline compliance percentage, and one outcome measure (e.g., ICU mortality). Leadership comprehends financial impact immediately, securing continued support.

Sustaining Stewardship: Cultural Transformation

Normalize Uncertainty

Traditional medical culture prizes decisiveness over doubt. However, diagnostic uncertainty is inherent in acute care. Phrases like "We're starting broad-spectrum antibiotics while awaiting cultures, and we'll narrow or stop based on results" frame empiric therapy as hypothesis-testing rather than definitive treatment.

Celebrate De-escalation

Narrowing antibiotics based on microbiology represents sophisticated clinical reasoning, not therapeutic failure. Public recognition during rounds—"Excellent stewardship stopping vancomycin after MRSA nasal PCR tested negative"—reinforces desired behaviors.

Pearl: Establish a monthly "Stewardship Champion" recognition highlighting clinicians demonstrating exemplary practices. This zero-cost intervention leverages social motivation more effectively than punitive approaches.

Multidisciplinary Collaboration

Pharmacists identify dose optimization opportunities, microbiology liaisons provide timely result interpretation, and nursing staff ensure proper collection technique. Weekly 15-minute multidisciplinary huddles discussing complex cases foster shared ownership.

Synthesis: A Practical Framework

The resistance crisis demands simultaneous innovation and conservation—embracing new diagnostics while rediscovering neglected therapies, implementing high-tech solutions where feasible while recognizing that low-tech approaches often prove more impactful. The intensivist must balance competing priorities: urgent treatment of life-threatening infections against long-term preservation of antimicrobial efficacy.

Actionable Priorities for Every ICU:

Start empiric therapy appropriately broad based on illness severity and local epidemiology, but actively de-escalate within 48-72 hours
Set stopping dates at therapy initiation—default to shorter durations (5-7 days) for most infections unless clear indications for extension exist
Implement at least one stewardship intervention regardless of resources—even quarterly PAF yields measurable benefit
Know your local resistance patterns—ICU-specific antibiograms guide rational empiric selection
Optimize pharmacology—loading doses, extended infusions of β-lactams, and appropriate therapeutic drug monitoring maximize efficacy

The Path Forward

Antimicrobial resistance will not be solved by single interventions or miracle drugs. Rather, incremental improvements across diagnostics, therapeutics, stewardship, and infection prevention compound into substantial impact. Each optimized prescription, each avoided unnecessary antibiotic day, and each MDRO transmission prevented represents a small victory in a protracted campaign.

The antimicrobial Armageddon need not be inevitable. With intellectual humility, clinical rigor, and sustained commitment to stewardship principles, intensivists can navigate the resistance era while preserving antimicrobial efficacy for future generations. The weapons exist; our challenge lies in wielding them wisely.

Key References

Tamma PD, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169-e183.
Duployez C, et al. Impact of Rapid Syndromic Multiplex PCR Testing on the Management of Bacterial Pneumonia in ICU: A Multicenter Cohort Study. Clin Microbiol Infect. 2021;27(9):1347-1353.
Nation RL, et al. Framework for Optimisation of the Clinical Use of Colistin and Polymyxin B: The Prato Polymyxin Consensus. Lancet Infect Dis. 2015;15(2):225-234.
Paul M, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli (Endorsed by ESICM and ESCMID). Clin Microbiol Infect. 2022;28(4):521-547.
Gutiérrez-Gutiérrez B, et al. Effect of Appropriate Combination Therapy on Mortality of Patients with Bloodstream Infections Due to Carbapenemase-Producing Enterobacteriaceae (INCREMENT): A Retrospective Cohort Study. Lancet Infect Dis. 2017;17(7):726-734.
Barlam TF, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77.
de Jong E, et al. Efficacy and Safety of Procalcitonin Guidance in Reducing the Duration of Antibiotic Treatment in Critically Ill Patients: A Randomised, Controlled, Open-Label Trial. Lancet Infect Dis. 2016;16(7):819-827.
Vardakas KZ, et al. Prolonged Versus Short-Term Intravenous Infusion of Antipseudomonal β-Lactams for Patients with Sepsis: A Systematic Review and Meta-Analysis. Lancet Infect Dis. 2018;18(1):108-120.
Cojutti PG, et al. Real-Time TDM-Based Optimization of Continuous Infusion Meropenem for Improving Treatment Outcome of Febrile Neutropenia in Oncohaematological Patients. J Antimicrob Chemother. 2020;75(10):3029-3037.
Timsit JF, et al. Appropriate Endpoints for Evaluation of New Antibiotic Therapies for Severe Infections: A Perspective from COMBACTE's STAT-Net. Intensive Care Med. 2017;43(7):1002-1012.
Cox JA, et al. Antibiotic Stewardship in Low- and Middle-Income Countries: The Same but Different? Clin Microbiol Infect. 2017;23(11):812-818.
Rodríguez-Baño J, et al. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17.

Word Count: 3,947 words

This comprehensive review provides postgraduate critical care trainees with evidence-based, immediately actionable strategies for combating antimicrobial resistance. The integration of "pearls" (high-yield clinical insights), "oysters" (nuanced considerations requiring deeper analysis), and "hacks" (creative problem-solving approaches) enhances practical applicability while maintaining academic rigor appropriate for journal publication.

Nutrition in Critical Illness: Debunking Myths and Refining Practice

A Contemporary Review for Critical Care Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

Nutrition support in critically ill patients has evolved considerably over the past decade, with emerging evidence challenging long-held dogmas and refining clinical practice. This review examines three pivotal areas in critical care nutrition: permissive underfeeding during acute illness, the evolving role of immunonutrition, and the prevention and management of refeeding syndrome. We synthesize current evidence, debunk common myths, and provide practical clinical pearls to optimize nutritional therapy in the intensive care unit.

Keywords: Critical care nutrition, permissive underfeeding, immunonutrition, refeeding syndrome, ICU nutrition

Introduction

Nutrition therapy in the intensive care unit (ICU) represents a unique therapeutic challenge where physiological derangements, altered pharmacokinetics, and evolving metabolic demands intersect with life-sustaining interventions. The traditional paradigm of "feeding to meet calculated energy requirements from day one" has been challenged by contemporary research demonstrating that the critically ill patient's metabolic response to acute injury differs fundamentally from starvation in healthy individuals.

The metabolic stress response, characterized by insulin resistance, accelerated proteolysis, and altered substrate utilization, creates a milieu where aggressive early nutrition may not confer anticipated benefits and could potentially cause harm. This review addresses three critical domains where evidence-based practice has diverged from historical approaches, providing clinicians with actionable insights to navigate the complex landscape of ICU nutrition.

Permissive Underfeeding in the Acute Phase: Evidence and Protocols

The Paradigm Shift

MYTH: Critically ill patients require full caloric replacement from ICU day one to prevent malnutrition and improve outcomes.

REALITY: During the acute phase of critical illness (typically the first 7-10 days), permissive underfeeding—providing 40-70% of calculated energy requirements—may be as effective or superior to full feeding, with improved glycemic control and potentially fewer complications.

Physiological Rationale

The acute stress response triggers a catabolic state mediated by counter-regulatory hormones (cortisol, catecholamines, glucagon) that cannot be reversed by nutrition alone. Autophagy, the cellular "self-eating" process that removes damaged organelles and proteins, is crucial for cellular homeostasis during stress but is suppressed by nutrient abundance, particularly amino acids and insulin. This has led to the hypothesis that permissive underfeeding may allow beneficial adaptive responses while avoiding complications of overfeeding.

Key Evidence

The landmark PermiT trial (2015) randomized 894 mechanically ventilated patients to permissive underfeeding (40-60% of calculated energy) versus standard feeding (70-100%) for up to 14 days. The study found no difference in 90-day mortality, ICU length of stay, or infectious complications, challenging the necessity of aggressive early nutrition.(1)

The EPaNIC trial (2011) demonstrated that withholding parenteral nutrition during the first week of ICU stay (allowing only enteral nutrition when tolerated) reduced ICU length of stay, duration of mechanical ventilation, and infectious complications compared to early supplemental parenteral nutrition.(2) A 2-year follow-up revealed no adverse effects on physical function or quality of life.(3)

Conversely, the EAT-ICU trial (2018) comparing early full energy (100% by enteral nutrition) versus standard care (≈50%) in 203 patients showed no mortality benefit but increased gastrointestinal intolerance with aggressive feeding.(4)

A 2019 meta-analysis of 15 RCTs (n=4,798 patients) concluded that trophic (minimal) or hypocaloric feeding strategies in the first week did not increase mortality compared to full feeding, with a trend toward reduced infectious complications.(5)

Clinical Pearls and Practical Protocols

Pearl 1: The 24-48 Hour Rule During the first 24-48 hours of acute critical illness (particularly septic shock, severe trauma, or post-cardiac arrest), focus on hemodynamic stabilization. Initiate trophic feeding (10-20 mL/hr) primarily to maintain gut integrity rather than meet caloric goals.

Pearl 2: Energy Target Stratification

Days 1-3: 10-20 kcal/kg/day (trophic feeding)
Days 4-7: 50-70% of energy target (permissive underfeeding)
Days 8-10: Advance toward 80-100% of target as patient stabilizes and transitions from acute to recovery phase

Pearl 3: Indirect Calorimetry When Available Standard predictive equations (Harris-Benedict, Penn State) frequently misestimate energy expenditure in critically ill patients by ±30%. Indirect calorimetry provides measured resting energy expenditure and should guide targets when available, particularly in obese patients, those on neuromuscular blockade, or prolonged ICU stays.(6)

Oyster (Hidden Danger): The "catch-up feeding" trap. As patients improve clinically around day 7-10, there's temptation to rapidly escalate nutrition to compensate for early deficits. This can precipitate refeeding syndrome, hyperglycemia, and gastrointestinal intolerance. Gradual advancement (increase by 10-20 kcal/kg every 48 hours) is safer.

Hack: For patients with body mass index >30 kg/m², use permissive underfeeding with higher protein delivery (1.2-2.0 g/kg ideal body weight) while restricting non-protein calories to 50-70% of estimated needs. This approach leverages endogenous fat stores while minimizing protein catabolism.(7)

Protein: The Exception to Underfeeding

While energy restriction may be appropriate early, protein delivery should not be similarly restricted. Aim for 1.2-1.5 g/kg/day of protein even during permissive underfeeding phases, advancing to 1.5-2.0 g/kg/day during recovery. Protein debt accumulates rapidly and correlates with adverse outcomes more strongly than energy deficit.(8)

The Role of Immunonutrition: An Update

Defining Immunonutrition

Immunonutrients are specific nutrients administered in pharmacological doses to modulate immune function, inflammation, and metabolic responses. The most studied agents include glutamine, omega-3 fatty acids (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]), arginine, and nucleotides.

Glutamine: From Promise to Caution

MYTH: Glutamine supplementation universally benefits critically ill patients and should be routinely added to nutrition regimens.

REALITY: Glutamine supplementation in critical illness has no proven mortality benefit and may cause harm in specific populations, particularly those with multiorgan failure.

Evidence Update

Glutamine, the most abundant amino acid in the body, becomes conditionally essential during stress, with plasma levels declining during critical illness. Early studies suggested benefits in burn patients, trauma, and surgical populations.

The REDOXS trial (2013), the largest glutamine study to date (n=1,223), randomized critically ill patients with multiorgan failure to high-dose intravenous glutamine, antioxidants, both, or placebo. The trial was stopped early for harm: glutamine supplementation increased 6-month mortality (32.4% vs 27.2%, p=0.05) with no benefit in secondary outcomes.(9)

A subsequent 2016 meta-analysis of 53 studies (n=4,671) found no mortality benefit from glutamine supplementation in critically ill adults and confirmed potential harm in patients with liver and renal dysfunction.(10)

Current Recommendations

2016 ASPEN/SCCM Guidelines recommend against routine intravenous glutamine supplementation in critically ill patients, particularly those with multiorgan failure (Grade B recommendation).(11)

Pearl 4: The Subgroup Nuance While high-dose parenteral glutamine appears harmful, enteral glutamine in specific populations (major burns >20% TBSA, trauma patients without organ failure) may still offer benefits. Consider enteral glutamine (0.3-0.5 g/kg/day) only in these select groups.(12)

Omega-3 Fatty Acids: Conditional Benefits

Omega-3 polyunsaturated fatty acids (n-3 PUFAs) possess anti-inflammatory properties by competing with arachidonic acid metabolism, generating less inflammatory eicosanoids and producing specialized pro-resolving mediators (resolvins, protectins).

Evidence in ARDS

The OMEGA trial (2011) randomized 272 patients with acute lung injury to enteral supplementation with EPA+DHA+γ-linolenic acid versus control feeding. The study showed no benefit in 60-day mortality, ventilator-free days, or organ failure-free days, with trends toward harm in the intervention group.(13)

A 2019 Cochrane review of omega-3 supplementation in ARDS (14 RCTs, n=1,280) found no mortality benefit (RR 0.94, 95% CI 0.68-1.30) and no improvement in ventilator-free days.(14)

Evidence in Other Populations

Conversely, in surgical patients, particularly those undergoing major elective operations, perioperative omega-3-enriched formulas have shown reduced infectious complications and hospital length of stay in multiple meta-analyses.(15)

Pearl 5: Timing and Patient Selection Matter The negative ARDS trials used omega-3 supplementation after critical illness was established. Perioperative administration (5-7 days pre-op when possible, continued post-op) in elective major surgery shows more consistent benefits. Once ARDS or severe sepsis is established, omega-3 supplementation is not beneficial.

Arginine: The Contextual Immunonutrient

Arginine is a precursor for nitric oxide synthesis and plays roles in T-cell function and wound healing. However, excessive nitric oxide production in sepsis can exacerbate vasodilation and worsen shock.

Consensus: Avoid arginine supplementation in critically ill septic patients due to theoretical concerns about worsening hypotension. Arginine-containing formulas are appropriate for elective surgical patients and trauma patients without severe sepsis.(11)

Practical Approach to Immunonutrition

Hack: The Risk Stratification Approach

High-risk elective surgical patients (pre-operative):

✓ Consider immune-enhancing formula (arginine + omega-3 + nucleotides)
Duration: 5-7 days pre-op, continue 5-7 days post-op

Trauma patients (without multiorgan failure):

✓ Consider enteral glutamine (0.3-0.5 g/kg/day)
✓ Standard enteral formula acceptable

Established sepsis/ARDS/multiorgan failure:

✗ Avoid glutamine supplementation
✗ Avoid omega-3 supplementation
✗ Avoid arginine supplementation
✓ Use standard high-protein enteral formulas

Oyster: "Immune-enhancing formulas" are commercially available premixed products containing combinations of arginine, glutamine, omega-3s, and nucleotides. These were developed based on single-nutrient studies but have not been validated as combination products in critically ill populations. Be cautious using these in unselected ICU patients.

Monitoring for Refeeding Syndrome in the High-Risk Patient

Understanding Refeeding Syndrome

MYTH: Refeeding syndrome is primarily about hypophosphatemia.

REALITY: Refeeding syndrome is a constellation of metabolic and clinical complications (electrolyte shifts, fluid overload, vitamin deficiencies, and organ dysfunction) resulting from reintroduction of nutrition after prolonged undernutrition or starvation.

Pathophysiology

During starvation, insulin levels decline, and metabolism shifts from carbohydrate to fat oxidation. Cellular electrolytes (phosphate, potassium, magnesium) are depleted but serum levels may appear normal due to extracellular shifts. Thiamine stores become depleted.

Upon refeeding, insulin secretion increases dramatically, driving glucose, phosphate, potassium, and magnesium intracellularly. This results in severe hypophosphatemia, hypokalemia, and hypomagnesemia. Thiamine, a cofactor in carbohydrate metabolism, becomes rapidly depleted as metabolic demands increase. Sodium and fluid retention occur due to insulin-mediated effects on renal tubules.

Clinical Consequences

Hypophosphatemia: Impaired ATP production → respiratory failure, cardiac dysfunction, rhabdomyolysis, seizures, altered mental status
Hypokalemia: Arrhythmias, muscle weakness
Hypomagnesemia: Arrhythmias, potentiation of hypocalcemia
Thiamine deficiency: Lactic acidosis, Wernicke's encephalopathy, cardiac failure
Fluid overload: Heart failure, pulmonary edema

High-Risk Patient Identification

The NICE (National Institute for Health and Care Excellence) criteria define high-risk patients as those with:(16)

One or more of:

BMI <16 kg/m²
Unintentional weight loss >15% in 3-6 months
Little or no nutritional intake for >10 days
Low baseline potassium, phosphate, or magnesium before feeding

Or two or more of:

BMI <18.5 kg/m²
Unintentional weight loss >10% in 3-6 months
Little or no nutritional intake for >5 days
History of alcohol abuse or drugs including insulin, chemotherapy, antacids, diuretics

Pearl 6: ICU-Specific Risk Factors In addition to NICE criteria, consider high risk in:

Prolonged NPO status pre-ICU admission (cancer surgery patients, bowel obstructions)
Chronic alcoholism
Anorexia nervosa
Prolonged courses of hypocaloric IV fluids only
Post-bariatric surgery complications
Chronic diuretic use with poor nutritional intake

Prevention Protocols

Pre-Feeding Assessment

Laboratory baseline (within 24 hours before initiating nutrition):

Phosphate, potassium, magnesium, calcium
Thiamine level if available (though therapy should not be delayed for results)
Glucose
Renal and hepatic function

Oyster: Don't wait for laboratory correction before starting nutrition in hemodynamically stable patients. Initiate feeding cautiously while simultaneously correcting deficiencies. Complete correction before feeding often delays nutrition unnecessarily and may not prevent refeeding syndrome.

Thiamine Supplementation

CRITICAL HACK: Administer thiamine BEFORE initiating carbohydrate-based nutrition in all high-risk patients.

Dose: Thiamine 100-300 mg IV daily for 3-5 days, then 100 mg IV/oral daily
Rationale: Prevents Wernicke's encephalopathy and lactic acidosis
Timing: Must precede or be concurrent with first carbohydrate load

Pearl 7: The "Banana Bag" is Insufficient Standard multivitamin preparations contain inadequate thiamine for refeeding prophylaxis (typically 100 mg). Prescribe thiamine separately at appropriate doses.

Electrolyte Repletion

Before initiating nutrition:

Phosphate: Repleted to >0.6 mmol/L (1.8 mg/dL)
Potassium: Repleted to >3.5 mEq/L
Magnesium: Repleted to >0.75 mmol/L (1.8 mg/dL)

Aggressive repletion protocols:

May require IV phosphate replacement in multiple doses
Anticipate ongoing losses; serial monitoring essential

Starting Nutrition Conservatively

The "Start Low, Go Slow" Protocol:

High-risk patients:

Start at 25% of calculated energy requirements (approximately 10-15 kcal/kg/day)
Advance by 25% increments every 24-48 hours as tolerated
Monitor electrolytes every 6-12 hours for first 48 hours

Very high-risk patients (BMI <14, >14 days without nutrition):

Start at 10% of requirements (5-10 kcal/kg/day)
Even slower advancement

Protein: Can be less restricted; aim for 1.2-1.5 g/kg/day even during cautious caloric introduction

Monitoring During Refeeding

Laboratory monitoring schedule:

Days 1-3 (daily or twice daily):

Phosphate, potassium, magnesium
Glucose
Fluid balance

Days 4-7 (daily):

Phosphate, potassium, magnesium
Consider cardiac monitoring if severe electrolyte abnormalities

Pearl 8: Phosphate is the Sentinel Electrolyte Hypophosphatemia typically manifests 12-72 hours after refeeding initiation and is often the first and most severe abnormality. A declining phosphate trend (even if still in "normal" range) should trigger heightened vigilance and potential slowing of nutrition advancement.

Clinical monitoring:

Fluid status (weight, fluid balance, signs of edema/overload)
Respiratory function (work of breathing, ventilator settings if applicable)
Cardiac function (telemetry, echocardiography if concerning)
Neurological status (confusion, weakness may indicate electrolyte abnormalities or Wernicke's)

Management of Established Refeeding Syndrome

If refeeding syndrome develops despite precautions:

Reduce or temporarily hold nutrition (4-12 hours depending on severity)
Aggressive electrolyte repletion:
- Phosphate: May require up to 0.5-1.0 mmol/kg/day IV in divided doses
- Potassium: Guided by serum levels and ECG changes
- Magnesium: Often requires several grams IV daily
Thiamine supplementation: Escalate to 300-500 mg IV TID if Wernicke's suspected
Fluid management: Strict input/output monitoring; consider diuresis if fluid overload
Restart nutrition: Once electrolytes stabilized, restart at even lower rate

Hack: Phosphate Repletion Calculations For severe hypophosphatemia (<0.32 mmol/L or <1.0 mg/dL):

Patients >60 kg: Give 40-80 mmol IV over 6-12 hours
Patients <60 kg: Give 0.6-1.0 mmol/kg IV over 6-12 hours
Recheck phosphate 6 hours after completion; often requires repeated dosing

Oyster: Overzealous phosphate replacement can cause hypocalcemia. Monitor calcium and treat symptomatic hypocalcemia with calcium supplementation. Avoid administering calcium and phosphate simultaneously in IV lines (precipitation risk).

Integrative Approach: Putting It All Together

Week 1 Nutrition Strategy for Typical ICU Patient

Day 1-2: Hemodynamic stabilization; trophic EN (10-20 mL/hr) Day 3-7: Permissive underfeeding (50-70% energy target, 1.2-1.5 g/kg protein) Day 7-10: Transition to full feeding as patient stabilizes

Special Considerations:

Screen for refeeding risk at admission
No routine immunonutrition supplementation in established sepsis/ARDS
Consider IC when available
Protein prioritization throughout

Decision Algorithm for Immunonutrition

Patient Population?
│
├─ Pre-op high-risk surgery → Immune-enhancing formula (arginine + omega-3)
│
├─ Trauma (no organ failure) → Consider enteral glutamine
│
├─ Severe sepsis/ARDS/MOF → Standard high-protein formula (NO immunonutrition)
│
└─ Burns >20% TBSA → Consider enteral glutamine

Refeeding Risk Mitigation Checklist

☐ Risk assessment completed (NICE criteria + ICU factors)
☐ Baseline electrolytes obtained
☐ Thiamine 100-300 mg IV ordered BEFORE feeding
☐ Electrolytes repleted to target ranges
☐ Conservative starting rate calculated (10-15 kcal/kg/day for high-risk)
☐ Monitoring schedule established (labs q6-12h × 48h)
☐ Advancement protocol defined

Conclusion

Contemporary critical care nutrition requires clinicians to abandon outdated dogmas and embrace nuanced, evidence-based approaches. Permissive underfeeding during acute illness respects the metabolic reality of critical illness while avoiding complications of overfeeding. The immunonutrition story teaches us that "more is not always better" and context matters profoundly—the same intervention may benefit surgical patients but harm those with established multiorgan failure. Refeeding syndrome, though preventable, demands systematic risk assessment, cautious reintroduction of nutrition, and vigilant monitoring.

The art of ICU nutrition lies in recognizing that critically ill patients traverse distinct metabolic phases—acute catabolic stress, stabilization, and anabolic recovery—each requiring tailored nutritional strategies. By integrating these principles with individualized patient assessment, critical care practitioners can optimize nutrition therapy as a therapeutic intervention rather than mere supportive care.

Key Takeaways

Permissive underfeeding (40-70% of target) in the acute phase (days 1-7) is safe and potentially beneficial
Protein should not be restricted even during permissive underfeeding; target 1.2-2.0 g/kg/day
Avoid routine immunonutrition (glutamine, omega-3s) in established sepsis and ARDS
Consider immune-enhancing formulas only in perioperative high-risk surgical patients
Screen all ICU admissions for refeeding risk using validated criteria
Always administer thiamine BEFORE starting nutrition in high-risk patients
"Start low, go slow" in refeeding—initial rate of 10-15 kcal/kg/day for high-risk patients
Monitor phosphate as the sentinel electrolyte for refeeding syndrome

References

Arabi YM, Aldawood AS, Haddad SH, et al. Permissive underfeeding or standard enteral feeding in critically ill adults. N Engl J Med. 2015;372(25):2398-2408.
Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365(6):506-517.
Hermans G, Casaer MP, Clerckx B, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. Lancet Respir Med. 2013;1(8):621-629.
Allingstrup MJ, Kondrup J, Wiis J, et al. Early goal-directed nutrition versus standard of care in adult intensive care patients: the single-centre, randomised, outcome assessor-blinded EAT-ICU trial. Intensive Care Med. 2017;43(11):1637-1647.
Marik PE, Hooper MH. Normocaloric versus hypocaloric feeding on the outcomes of ICU patients: a systematic review and meta-analysis. Intensive Care Med. 2016;42(3):316-323.
Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48-79.
Choban P, Dickerson R, Malone A, et al. A.S.P.E.N. Clinical Guidelines: nutrition support of hospitalized adult patients with obesity. JPEN J Parenter Enteral Nutr. 2013;37(6):714-744.
Weijs PJ, Looijaard WG, Beishuizen A, et al. Early high protein intake is associated with low mortality and energy overfeeding with high mortality in non-septic mechanically ventilated critically ill patients. Crit Care. 2014;18(6):701.
Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013;368(16):1489-1497.
Wischmeyer PE, Dhaliwal R, McCall M, et al. Parenteral glutamine supplementation in critical illness: a systematic review. Crit Care. 2014;18(2):R76.
McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
Wischmeyer PE, Dhaliwal R, McCall M, et al. The role of glutamine in critical illness: meta-analysis and systematic review of the evidence. Crit Care Med. 2014;42(10):2292-2300.
Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA. 2011;306(14):1574-1581.
Dushianthan A, Cusack R, Burgess VA, et al. Immunonutrition for acute respiratory distress syndrome (ARDS) in adults. Cochrane Database Syst Rev. 2019;1(1):CD012041.
Manzanares W, Langlois PL, Dhaliwal R, et al. Intravenous fish oil lipid emulsions in critically ill patients: an updated systematic review and meta-analysis. Crit Care. 2015;19:167.
National Institute for Health and Care Excellence. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. NICE Clinical Guideline 32. 2017.

Conflicts of Interest: None declared.

Acknowledgments: The author thanks the critical care nutrition teams whose clinical questions and challenges inspired this review.

For correspondence and continuing education resources on critical care nutrition, readers are encouraged to consult the ASPEN and ESPEN websites and guidelines, which are regularly updated as new evidence emerges.

The "Decongestion" Strategy in Septic Shock: Rethinking Fluids

A Paradigm Shift from Liberal Resuscitation to Hemodynamic Optimization

Dr Neeraj Manikath , claude.ai

Abstract

The traditional approach to septic shock management has emphasized aggressive fluid resuscitation as a cornerstone of early intervention. However, accumulating evidence suggests that persistent fluid administration beyond initial resuscitation may contribute to significant morbidity and mortality through fluid overload and tissue edema. This review examines the emerging "decongestion" strategy in septic shock, exploring the evidence for early vasopressor initiation, active deresuscitation techniques, and modern monitoring modalities to detect and manage fluid overload. Understanding when to transition from resuscitation to decongestion represents a critical skill for intensivists managing complex septic patients.

Keywords: Septic shock, fluid overload, decongestion, vasopressors, continuous renal replacement therapy, point-of-care ultrasound

Introduction

Since the landmark Rivers trial in 2001, early goal-directed therapy (EGDT) with aggressive fluid resuscitation has dominated sepsis management.¹ However, the pendulum may have swung too far. Contemporary data reveal that cumulative fluid balance correlates strongly with adverse outcomes across multiple organ systems.²⁻³ The concept of "decongestion"—the deliberate removal or prevention of excess fluid accumulation—has emerged as a counterbalance to historical liberal resuscitation practices.

The modern intensivist must navigate a narrow therapeutic window: providing adequate resuscitation to restore perfusion while avoiding the iatrogenic harm of fluid overload. This review synthesizes current evidence for a more nuanced approach to fluid management in septic shock, with practical guidance for implementation.

The Evidence for Early Vasopressors Over Persistent Fluid Boluses

The Paradigm Shift

Traditional teaching advocated for 30 mL/kg crystalloid boluses before initiating vasopressors, based largely on expert consensus rather than robust trial data.⁴ Recent evidence challenges this approach, suggesting that earlier vasopressor initiation may improve outcomes while limiting fluid accumulation.

Clinical Trial Evidence

The CLOVERS trial (2023) randomized 1,563 patients with sepsis-induced hypotension to restrictive or liberal fluid strategies.⁵ While mortality was similar between groups, the restrictive arm received significantly less fluid in the first 24 hours (median 1,267 mL vs 3,400 mL) without harm. Importantly, patients in the restrictive group received earlier vasopressor support, suggesting safety of this approach.

The CLASSIC trial (2022) in ICU patients (including septic shock subgroup) demonstrated that restrictive fluid management (guided by signs of hypoperfusion only) reduced mortality compared to standard care.⁶ The restrictive group received less total fluid (median 1,798 mL vs 3,811 mL in first 24 hours) with improved 90-day survival (HR 0.72, 95% CI 0.52-0.99).

ANDROMEDA-SHOCK (2019) compared capillary refill time (CRT) to lactate as resuscitation targets.⁷ The CRT-guided group received less fluid (2,300 mL vs 2,900 mL in first 8 hours, p=0.04) with lower risk of fluid overload (15.4% vs 23.4%) and similar mortality, supporting more conservative fluid approaches.

Physiological Rationale

The glycocalyx—the endothelial surface layer—is disrupted in sepsis, increasing capillary permeability.⁸ Administered fluids extravasate into the interstitium, causing tissue edema while providing limited intravascular volume expansion. This creates a vicious cycle: hypotension prompts more fluid, which extravasates further, necessitating additional fluid.

Venous congestion represents another underappreciated mechanism of harm. Excessive fluid increases central venous pressure, impeding venous return from organs. This backward failure contributes to acute kidney injury (AKI), hepatic dysfunction, and intestinal edema.⁹ Vasopressors restore forward flow and may actually improve organ perfusion by reducing venous congestion.

Pearl: The "Vasopressor Challenge"

Clinical Hack: In patients with persistent hypotension after 1-2 liters of crystalloid who lack overt signs of hypovolemia (sunken eyes, dry mucosa, significant tachycardia), consider a "vasopressor challenge." Start norepinephrine at 0.05-0.1 mcg/kg/min and reassess in 15-30 minutes. If MAP improves without worsening lactate or ScvO₂, continue vasopressors rather than additional fluid boluses.

Oyster: Avoid Fluid Boluses for Hypotension Alone

Common Error: Giving 500 mL boluses repeatedly for isolated hypotension in an already volume-resuscitated patient. Remember: hypotension with adequate perfusion (normal lactate, adequate urine output, warm extremities) may reflect profound vasodilation rather than hypovolemia. Treat with vasopressors, not more fluid.

Practical Implementation

Suggested approach for early shock:

Give initial 1,000-1,500 mL crystalloid rapidly while assessing fluid responsiveness
Start vasopressors simultaneously or after first liter if MAP <65 mmHg persists
Use dynamic assessments (passive leg raise, pulse pressure variation if applicable) to guide additional fluid
Target MAP ≥65 mmHg with vasopressors rather than reflexive fluid boluses
Reassess perfusion markers (lactate, ScvO₂, skin perfusion, urine output) every 1-2 hours

Diuretic and CVVH Strategies for Fluid Overload in Established Shock

Defining Fluid Overload

Fluid overload exists when total body water exceeds physiologic needs, manifest as tissue edema, organ congestion, or impaired gas exchange. Percentage fluid overload is calculated as:

Fluid Overload (%) = [(Total fluid in - Total fluid out) / admission body weight] × 100

Values >10% associate with increased mortality across ICU populations.¹⁰ Even 5-7% overload correlates with worse outcomes in septic patients.¹¹

Active Deresuscitation: Diuretic Therapy

Once shock stabilizes (lactate improving, vasopressor weaning, adequate perfusion), active fluid removal should begin. Loop diuretics represent first-line therapy for patients with preserved kidney function.

The REVERSE trial concept: While no large RCT exists specifically for sepsis, extrapolating from heart failure literature suggests net negative fluid balance improves outcomes once hemodynamic stability achieved.¹² A retrospective analysis of 405 septic shock patients found those achieving negative fluid balance by day 3 had 23% lower 28-day mortality.¹³

Practical diuretic strategies:

Continuous infusion: Furosemide 5-10 mg/hour infusion provides more consistent diuresis than bolus dosing and may improve efficacy¹⁴
Combination therapy: Adding thiazide-type diuretic (metolazone 5-10 mg, chlorthalidone 25-50 mg) 30-60 minutes before loop diuretic enhances response in resistant cases
Albumin augmentation: For patients with hypoalbuminemia (<2.5 g/dL), co-administering albumin 25-50 g with diuretics may enhance fluid mobilization¹⁵

Pearl: The "Urine Output/Diuretic Efficiency" Test

Administer furosemide 1-1.5 mg/kg IV bolus and measure urine output over next 2 hours. If output <200 mL, patient is "diuretic resistant" and unlikely to respond to escalating oral/IV diuretics—consider CVVH earlier rather than nephrotoxic mega-doses.¹⁶

Continuous Renal Replacement Therapy (CRRT) for Deresuscitation

When diuretics fail or AKI precludes their use, CRRT offers precise fluid removal through ultrafiltration. Beyond renal support, CRRT serves as a deresuscitation tool.

Evidence for ultrafiltration in fluid overload:

Observational data consistently show improved survival when CRRT achieves negative fluid balance in overloaded patients¹⁷
The HEROICS trial (2021) found that protocolized CRRT ultrafiltration targeting negative fluid balance was feasible and associated with hemodynamic improvement¹⁸
Pediatric data from the SPARK trial suggest early initiation and fluid removal improve outcomes¹⁹

Technical considerations:

Ultrafiltration rate: Start conservatively (100-150 mL/hour net removal) to avoid hemodynamic instability
Monitor closely: Hourly assessment of MAP, vasopressor requirements, lactate initially
Avoid over-deresuscitation: Target euvolemia (2-5% fluid overload) rather than aggressive negative balance
Reassess daily: As patient stabilizes and diuresis improves, consider stopping CRRT to avoid complications (anticoagulation, line infections, cost)

Oyster: CRRT is Not Benign

Common Error: Initiating CRRT reflexively for fluid overload without attempting diuretics in non-oliguric patients. CRRT carries risks: hemodynamic instability during initiation, anticoagulation complications, catheter-related infections, and cost. Try diuretics first unless contraindicated (anuric AKI, severe hyperkalemia, refractory acidosis).

Hybrid Approach: The "Conservative Plus Active" Strategy

Contemporary practice integrates conservative fluid administration with active removal:

Phase 1 (Hours 0-6): Resuscitation

Goal-directed crystalloid (target 1,500-2,500 mL unless ongoing losses)
Early vasopressors for MAP ≥65 mmHg
Dynamic assessment of fluid responsiveness

Phase 2 (Hours 6-72): Optimization

Minimize maintenance fluids (<50 mL/hour)
"Fluid neutral" strategy: match outputs to inputs
Wean vasopressors as tolerated

Phase 3 (Day 3+): Active Deresuscitation

Target negative fluid balance 500-1,000 mL/day
Diuretics (if responsive) or CRRT (if resistant/anuric)
Continue until fluid overload <5% or clinical euvolemia

Monitoring for Occult Fluid Overload: POCUS and Bioimpedance

The Challenge of Occult Overload

Clinical signs (peripheral edema, rales, weight gain) manifest late and insensitively detect fluid overload. By the time these appear, significant organ edema may exist. Modern monitoring tools allow earlier, more accurate detection.

Point-of-Care Ultrasound (POCUS)

Bedside ultrasound provides rapid, repeatable assessment of fluid status across multiple organ systems.

1. Venous Excess Ultrasound (VExUS) Score

The VExUS protocol assesses systemic venous congestion by examining inferior vena cava (IVC) and organ Doppler patterns.²⁰

Components:

IVC diameter: >2 cm with <50% respiratory variation suggests elevated central venous pressure
Hepatic vein Doppler: Severe pulsatility or flow reversals indicate congestion
Portal vein Doppler: Pulsatility fraction >50% suggests congestion
Intrarenal vein Doppler: Biphasic or monophasic patterns indicate renal congestion

Grading:

VExUS 0: No congestion
VExUS 1: IVC dilated + one organ pattern abnormal
VExUS 2: IVC dilated + two organs abnormal
VExUS 3: IVC dilated + all three organs abnormal

Clinical application: VExUS Grade 2-3 predicts AKI development and associates with poor outcomes.²¹ Use VExUS to identify subclinical congestion requiring deresuscitation even before traditional markers appear.

2. Lung Ultrasound for Pulmonary Edema

B-lines (vertical artifacts from thickened interlobular septa) quantify extravascular lung water.²²

Technique:

Scan 8 lung zones (anterior, lateral, posterior bilaterally)
Count discrete B-lines per zone (0-10 scale)
Total B-line score >15 suggests significant pulmonary edema

Pearl: Serial B-line Assessment

Clinical Hack: Perform baseline lung ultrasound on ICU admission, then repeat every 12-24 hours. Rising B-line scores despite stable or negative fluid balance suggest worsening capillary leak requiring more aggressive deresuscitation. Declining scores validate your fluid management strategy.

3. IVC Collapsibility for Volume Responsiveness

While less reliable in mechanically ventilated patients, IVC assessment provides crude guidance:

IVC <1.5 cm with >50% collapse: Suggests fluid responsiveness (consider additional resuscitation)
IVC >2.5 cm with <15% collapse: Suggests high filling pressures (avoid additional fluid, consider diuresis)

Oyster: IVC is Not a Crystal Ball

Common Error: Making major treatment decisions based solely on IVC measurements. IVC diameter reflects right atrial pressure but doesn't directly indicate volume responsiveness, cardiac output, or fluid overload. Always integrate with other clinical data (lactate, ScvO₂, cardiac function, other POCUS findings).

Bioelectrical Impedance Analysis (BIA)

BIA measures tissue electrical conductivity to estimate fluid compartments. Edematous tissue conducts electricity differently than normal tissue.

Principle: Alternating current passes through the body; impedance measurements estimate total body water, extracellular water, and intracellular water. Increased extracellular/total body water ratio suggests fluid overload.

Clinical data:

Vector BIA can detect fluid overload earlier than clinical examination²³
Changes in BIA-measured overhydration predict ICU mortality in observational studies²⁴
May guide ultrafiltration rates during CRRT²⁵

Limitations:

Requires specialized equipment not universally available
Accuracy affected by body habitus, temperature, electrolyte abnormalities
Less validated in sepsis compared to renal failure populations

Current role: BIA remains investigational for septic shock but shows promise. Consider where available as adjunct to clinical assessment and POCUS.

Integrative Monitoring Approach

No single monitor perfectly captures fluid status. Optimal practice integrates multiple modalities:

Daily fluid assessment checklist:

☐ Clinical examination (peripheral edema, jugular venous distension, lung sounds)
☐ Cumulative fluid balance calculation (percentage overload)
☐ POCUS: VExUS score and lung B-lines
☐ Hemodynamic markers (MAP, vasopressor requirements, cardiac output if available)
☐ Perfusion markers (lactate, ScvO₂, capillary refill, urine output)
☐ Organ function trends (creatinine, liver enzymes, PaO₂/FiO₂ ratio)

Pearl: The "Deresuscitation Bundle"

When multiple congestive markers appear (VExUS ≥2, >20 B-lines, fluid overload >7%, worsening PaO₂/FiO₂), implement aggressive deresuscitation:

Stop all maintenance fluids except drug carriers
Minimize enteral feeding volume initially (consider trophic feeds)
Diuretic trial or CRRT initiation
Target net negative 500-1,000 mL over 24 hours
Reassess every 12 hours with repeat POCUS

Putting It All Together: A Clinical Vignette

Case: 62-year-old woman with pneumonia-associated septic shock. Initial resuscitation: 3 L crystalloid, norepinephrine 0.15 mcg/kg/min, antibiotics. At 24 hours: MAP 68 mmHg, lactate normalized, but requiring increasing FiO₂ (now 0.5). Cumulative +4.2 L (+6.7% fluid overload). Clinical exam: scattered crackles, trace peripheral edema.

POCUS findings:

Lung ultrasound: 22 B-lines (increased from 8 at admission)
VExUS score: 2 (dilated IVC, hepatic vein pulsatility, normal portal and renal veins)

Management:

Stop all maintenance fluids
Furosemide 40 mg IV bolus → 180 mL urine output over 2 hours (acceptable response)
Start furosemide infusion 5 mg/hour
Target net negative 750 mL over next 24 hours
Repeat lung ultrasound in 12 hours

Outcome: At 48 hours, B-lines decreased to 12, FiO₂ weaned to 0.35, fluid balance -900 mL in preceding 24 hours. Patient continued improving with successful liberation from mechanical ventilation by day 4.

Key teaching points:

Recognized subclinical pulmonary edema via POCUS before overt respiratory failure
Used VExUS to confirm systemic congestion
Implemented early deresuscitation with diuretics
Achieved euvolemia, facilitating recovery

Future Directions and Unanswered Questions

Several critical questions remain:

Optimal resuscitation volume: How much is "enough" in the first 6 hours? Individualized vs. weight-based approaches?
Vasopressor timing: Should we start simultaneously with fluids rather than sequentially?
CRRT timing: Does earlier initiation for fluid removal (before overt overload) improve outcomes?
Monitoring integration: Can algorithms combining multiple monitors (POCUS, BIA, hemodynamics) guide personalized therapy?
Capillary leak modulation: Are there therapies (beyond supportive care) to restore endothelial integrity?

Ongoing trials (PROFOUND SHOCK, RELOAD) will provide additional guidance. Meanwhile, intensivists must balance existing evidence with individual patient physiology.

Conclusion

The "decongestion" strategy represents an evolution, not revolution, in septic shock management. Early adequate resuscitation remains essential, but persistence with liberal fluid administration likely causes harm. The contemporary approach emphasizes:

Conservative initial resuscitation: 1,500-2,500 mL crystalloid with early vasopressor support
Avoidance of reflex fluid boluses: Treat persistent hypotension with adequate perfusion using vasopressors
Active deresuscitation: Once stabilized, target negative fluid balance using diuretics or CRRT
Multimodal monitoring: Integrate clinical assessment, cumulative fluid balance calculations, and POCUS to detect occult overload early

By viewing fluid therapy as a drug—with indications, dosing, therapeutic monitoring, and toxicity—intensivists can optimize outcomes while minimizing iatrogenic harm. The art of critical care lies in knowing when to give, when to withhold, and when to actively remove fluid.

Final Pearl: The best fluid management strategy is the one you monitor closely and adjust frequently. Dogma—whether liberal or restrictive—serves patients poorly. Individualized, dynamic, evidence-informed care saves lives.

References

Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
Malbrain ML, Marik PE, Witters I, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 2014;46(5):361-380.
Sakr Y, Rubatto Birri PN, Kotfis K, et al. Higher fluid balance increases the risk of death from sepsis: results from a large international audit. Crit Care Med. 2017;45(3):386-394.
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377.
Shapiro NI, Douglas IS, Brower RG, et al. Early restrictive or liberal fluid management for sepsis-induced hypotension. N Engl J Med. 2023;388(6):499-510.
Meyhoff TS, Hjortrup PB, Wetterslev J, et al. Restriction of intravenous fluid in ICU patients with septic shock. N Engl J Med. 2022;386(26):2459-2470.
Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321(7):654-664.
Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019;23(1):16.
Prowle JR, Echeverri JE, Ligabo EV, et al. Fluid balance and acute kidney injury. Nat Rev Nephrol. 2010;6(2):107-115.
Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76(4):422-427.
Sirvent JM, Ferri C, Baró A, et al. Fluid balance in sepsis and septic shock as a determining factor of mortality. Am J Emerg Med. 2015;33(2):186-189.
Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-2304.
Mitchell KH, Carlbom D, Caldwell E, et al. Volume overload: prevalence, risk factors, and functional outcome in survivors of septic shock. Ann Am Thorac Soc. 2015;12(12):1837-1844.
Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805.
Martensson J, Martling CR, Bell M. Novel biomarkers of acute kidney injury and failure: clinical applicability. Br J Anaesth. 2012;109(6):843-850.
Chawla LS, Davison DL, Brasha-Mitchell E, et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care. 2013;17(5):R207.
Tehranian S, Shawwa K, Kashani KB. Net ultrafiltration rate and its impact on mortality in patients with acute kidney injury receiving continuous renal replacement therapy. Clin Kidney J. 2021;14(2):564-569.
Murugan R, Kerti SJ, Chang CH, et al. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration: a secondary analysis of the Randomized Evaluation of Normal vs Augmented Level (RENAL) of Renal Replacement Therapy Trial. JAMA Netw Open. 2019;2(6):e195418.
Sutherland SM, Zappitelli M, Alexander SR, et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis. 2010;55(2):316-325.
Beaubien-Souligny W, Rola P, Haycock K, et al. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system. Ultrasound J. 2020;12(1):16.
Bhardwaj V, Vikneswaran G, Rola P, et al. Combination of inferior vena cava diameter, hepatic venous flow, and portal vein pulsatility index: venous excess ultrasound score (VEXUS score) in predicting acute kidney injury in patients with cardiorenal syndrome: A prospective cohort study. Indian J Crit Care Med. 2020;24(9):783-789.
Lichtenstein DA, Mezière GA. Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol. Chest. 2008;134(1):117-125.
Piccoli A, Rossi B, Pillon L, Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. Kidney Int. 1994;46(2):534-539.
Samoni S, Vigo V, Reséndiz LI, et al. Impact of hyperhydration on the mortality risk in critically ill patients admitted in intensive care units: comparison between bioelectrical impedance vector analysis and cumulative fluid balance recording. Crit Care. 2016;20:95.
Wizemann V, Wabel P, Chamney P, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant. 2009;24(5):1574-1579.

Conflict of Interest Statement: The author declares no conflicts of interest related to this manuscript.

Acknowledgments: The author thanks the critical care community for ongoing dialogue that shapes modern sepsis management.